Program
Palforzia
Also written as “DBV712 250 mcg”, “DBV712” and “Viaskin Peanut 250mcg”.
Its studies are mostly in Peanut Hypersensitivity, led by DBV Technologies.
Furthest: phase 3, since Nov 19, 20155 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| DBV Technologies | 52 open or running | phase 3since Nov 19, 2015 | Nov 19, 2015 | Nov 2026phase 3 · NCT07003919 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2015First study: phase 3 study in Peanut HypersensitivityFirst studyNCT02636699 · 500 enrolled · United States, Australia, Canada and more
- Nov 21, 2017Phase 1 study in Peanut HypersensitivityNCT03352726 · 27 enrolled · United States
- Feb 19, 2019Phase 3 study in Peanut HypersensitivityNCT03859700 · 304 enrolled · United States
- Feb 14, 2023Phase 3 study in Peanut HypersensitivityNCT05741476 · 600 enrolled · United States, Australia, Canada and more
- May 27, 2025Phase 3 study in HypersensitivityNCT07003919 · 480 enrolled · United States, Australia, Canada and more
Ahead
- Nov 2026Primary completion: phase 3 study in HypersensitivityNCT07003919
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07003919Hypersensitivity · United States, Australia, Canada and more | 3 | Active, not recruiting | Nov 2026 | 480 |
| NCT05741476Peanut Hypersensitivity · United States, Australia, Canada and more | 3 | Active, not recruiting | Nov 6, 2025 | 600 |
| NCT03859700Peanut Hypersensitivity · United States | 3 | Completed | May 13, 2025 | 304 |
| NCT03352726Peanut Hypersensitivity · United States | 1 | Completed | Jun 29, 2018 | 27 |
| NCT02636699Peanut Hypersensitivity · United States, Australia, Canada and more | 3 | Completed | Aug 18, 2017 | 500 |
How it is read
Names in the registry
- “DBV712 250 mcg”, 2 entries
- “DBV712”, 2 entries
- “Viaskin Peanut 250mcg”, 1 entry
- “DBV712 IHRP”, 1 entry
Conditions, from the studies’ own filings
- Peanut Hypersensitivity, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.